Article
ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Atherosclerosis. Supplements - 1 Nov 2017
Rodionov Roman N, Heinrich Annett, Brilloff Silke, Jarzebska Natalia, Martens-Lobenhoffer Jens, Bode-Böger Stefanie M, Todorov Vladimir T, Hugo Christian P M, Weiss Norbert, Hohenstein Bernd
Abstract excerpt
BACKGROUND AND AIMS: Cardiovascular disease is the major cause of morbidity and mortality in the world. Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk. Association studies suggest that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthases, plays a role in the pathogenesis of diabetic nephropathy. The major pathway of ADMA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.